ZFHX3 mutations were also associated with a significant survival benefit across all patients (Fig. 7G), and were most common in colorectal cancer patients, followed by bladder cancer, melanoma, and NSCLC patients (Fig. 7H). This evidence concerns the gene ZFHX3 and urinary bladder cancer.